Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
16
APLT Quote, Financials, Valuation and Earnings
Last price:
$0.12
Seasonality move
:
28.77%
Day range:
$0.12 - $0.13
52-week range:
$0.10 - $1.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.83x
P/B ratio:
1.80x
Volume:
3.9M
Avg. volume:
21.6M
1-year change:
-85.77%
Market cap:
$18.1M
Revenue:
$455K
EPS (TTM):
-$0.10
Analysts' Opinion
-
Consensus RatingApplied Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $0.25, Applied Therapeutics, Inc. has an estimated upside of 99.68% from its current price of $0.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.25 representing 100% downside risk from its current price of $0.13.
Fair Value
-
According to the consensus of 4 analysts, Applied Therapeutics, Inc. has 99.68% upside to fair value with a price target of $0.25 per share.
APLT vs. S&P 500
-
Over the past 5 trading days, Applied Therapeutics, Inc. has overperformed the S&P 500 by 4.57% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Applied Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Applied Therapeutics, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Applied Therapeutics, Inc. reported revenues of $1M.
Earnings Growth
-
Applied Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Applied Therapeutics, Inc. reported earnings per share of -$0.13.
Enterprise value:
8.6M
EV / Invested capital:
4.45x
Price / LTM sales:
17.83x
EV / EBIT:
--
EV / Revenue:
8.62x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$596K
Return On Assets:
-28.18%
Net Income Margin (TTM):
-1813.8%
Return On Equity:
-77.88%
Return On Invested Capital:
-70.3%
Operating Margin:
-1675.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $10.7M | $456K | $1M | $122K | $1M | |
| Gross Profit | $10.2M | -$7K | $596K | $18K | $889K | |
| Operating Income | -$62.5M | -$86.8M | -$98.4M | -$29.7M | -$16.8M | |
| EBITDA | -$62M | -$86.3M | -$98M | -$29.6M | -$16.6M | |
| Diluted EPS | -$1.32 | -$1.74 | -$0.10 | -$0.48 | -$0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $116.9M | $55.5M | $44.5M | $104.6M | $31.7M | |
| Total Assets | $118.5M | $56.7M | $45.2M | $106.6M | $34.4M | |
| Current Liabilities | $30.8M | $46.5M | $55.5M | $99M | $32.9M | |
| Total Liabilities | $31.8M | $47.1M | $56.2M | $100.7M | $34.9M | |
| Total Equity | $86.7M | $9.6M | -$11M | $5.9M | -$561K | |
| Total Debt | $1.4M | $536K | $735K | $1.7M | $2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$54.1M | -- | -$86.8M | -$23.3M | -$18.4M | |
| Cash From Investing | $7M | -- | -- | -- | -- | |
| Cash From Financing | $44.2M | -- | -$75K | -- | -$75K | |
| Free Cash Flow | -$54.1M | -- | -$86.8M | -$23.3M | -$18.4M | |
APLT
Sector
Market Cap
$18.1M
$28.4M
Price % of 52-Week High
8.35%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-0.55%
-1.49%
1-Year Price Total Return
-85.77%
-16.67%
Beta (5-Year)
1.989
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.13
200-day SMA
Sell
Level
$0.51
Bollinger Bands (100)
Sell
Level
0.23 - 0.99
Chaikin Money Flow
Sell
Level
-249M
20-day SMA
Sell
Level
$0.20
Relative Strength Index (RSI14)
Sell
Level
27.01
ADX Line
Sell
Level
38
Williams %R
Buy
Level
-84.0506
50-day SMA
Sell
Level
$0.64
MACD (12, 26)
Sell
Level
-0.12
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
202.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.0833)
Sell
CA Score
(Annual)
Level (-8.1105)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (9.8955)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, APLT has received 0 Buy ratings 4 Hold ratings, and 0 Sell ratings. The APLT average analyst price target in the past 3 months is $0.25.
-
Where Will Applied Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Applied Therapeutics, Inc. share price will rise to $0.25 per share over the next 12 months.
-
What Do Analysts Say About Applied Therapeutics, Inc.?
Analysts are divided on their view about Applied Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Applied Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $0.25.
-
What Is Applied Therapeutics, Inc.'s Price Target?
The price target for Applied Therapeutics, Inc. over the next 1-year time period is forecast to be $0.25 according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is APLT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Applied Therapeutics, Inc. is a Hold. 4 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of APLT?
You can purchase shares of Applied Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Applied Therapeutics, Inc. shares.
-
What Is The Applied Therapeutics, Inc. Share Price Today?
Applied Therapeutics, Inc. was last trading at $0.12 per share. This represents the most recent stock quote for Applied Therapeutics, Inc.. Yesterday, Applied Therapeutics, Inc. closed at $0.13 per share.
-
How To Buy Applied Therapeutics, Inc. Stock Online?
In order to purchase Applied Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get APLT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
APLT
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
1.80x
1.81x
Price / LTM sales
17.83x
1.58x
Growth Metrics
APLT
Sector
Revenue growth
719.67%
4.62%
Earnings growth
72.54%
10.7%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.14
-$0.21
Profitability
APLT
Sector
Profitability FY 2024
$30K
$3.6M
Return on invested capital
-70.3%
-31.84%
Return on assets
-28.18%
-27.96%
Return on equity
-77.88%
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
12
Balance Sheet
APLT
Sector
Total cash
$11.9M
$26.4M
Short term investments
--
$25.7M
Total assets
$86.7M
$76.9M
Long term debt
$2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 4.74% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 0.04% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is down 0.54% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
